Patents by Inventor Kihwa KANG

Kihwa KANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-FGFR1c antibody-FGF21 fusion proteins
    Patent number: 10519240
    Abstract: The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ?Klotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided are methods of treating various metabolic disorders by administering the FGF21R agonists and/or anti-FGF21 antibodies to a subject in need thereof.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: December 31, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: George D. Yancopoulos, Andrew J. Murphy, Jesper Gromada, David R. Buckler, Kihwa Kang
  • FGF21 Receptor Agonists And Uses Thereof
    Publication number: 20170174769
    Abstract: The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ?Klotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided are methods of treating various metabolic disorders by administering the FGF21R agonists and/or anti-FGF21 antibodies to a subject in need thereof.
    Type: Application
    Filed: March 25, 2015
    Publication date: June 22, 2017
    Inventors: George D. YANCOPPULOS, Andrew J. MURPHY, Jesper GROMADA, David R. BUCKLER, Kihwa KANG